FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Insys Therapeutics Agrees to $150 Million Fine with DoJ

Insys Therapeutics reaches an agreement in principle with the Department of Justice to pay $150 million to settle a civil and criminal investigation i...

Medical Devices

FDA Clears iCADs Latest Breast Density Software

FDA clears an iCAD 510(k) for its latest artificial intelligence software solution PowerLook Density Assessment Version 3.4 for breast density.

Human Drugs

AstraZeneca Settles Texas Medicaid Suits for $110 Million

Texas attorney general Ken Paxton says AstraZeneca will pay the state $110 million to settle suits over fraudulent Medicaid marketing of its Seroquel ...

Human Drugs

Dissolution Testing and Acceptance Criteria Guidance

FDA issues a guidance with recommendations for submission of NDAs, INDs, or ANDAs for orally administered immediate-release drug products containing h...

Human Drugs

FDA Approves First CGT Generic Drugs

FDA uses the Competitive Generic Therapy pathway to approve several strengths of Apotex potassium chloride solution.

Medical Devices

Rupture of Membranes Tests Have Limits: FDA

FDA cautions healthcare professionals not to rely on rupture of membranes tests alone and instead use them as part of a broader clinical assessment.

Medical Devices

Qiagen Sciences Recalls Membrane Rupture Test

Qiagen Sciences recalls the AmniSure ROM Test due to a potential manufacturing defect causing the control line to not display.

Federal Register

27 ANDAs Being Withdrawn by FDA

Federal Register notice: FDA withdraws 27 ANDAs from multiple applicants after the application holders told the agency that the drug products were no ...

Human Drugs

CGMP Deviations at Les Produits Chimiques

FDA warns Canadas Les Produits Chimiques about deviations from CGMP regulations for active pharmaceutical ingredients.

Medical Devices

Dont Impose 30-Day SIR Deadline: AdvaMed

Two medical device stakeholders urge FDA not to lengthen the review time for Q-Sub submission issue requests filed more than 30 days after a marketing...